Editorial Comment
Myosin and Why Hearts Fail R. John Solaro, PhD T he search for the answer to why hearts fail offers some exciting new leads. The genetic defect in one inherited form of heart disease, familial hypertrophic cardiomyopathy (FHC), has been localized to a region of chromosome 14 encoding for myosin heavy chains.1'2 Point mutations in the ,3-isoform of the heavy chain2 and mutant hybrid forms of the a-and 83-heavy chains1 have been identified. Compared with controls, however, myofilaments from hearts of patients with FHC show no clearly evident changes in functional properties. Moreover, how the mutant myosins could instigate the manifestations and course of the disease is not yet clear. In idiopathic dilated cardiomyopathy (IDC), there are clear changes in the functional properties of the myofilaments, but exactly what the cause might be has eluded researchers. A promising idea was that IDC is associated with a change in transcriptional activity of members of the multigene myosin heavy chain family. This has not proven to be the case; instead, IDC is associated with a decrease in levels of message for phospholamban, a regulatory protein associated with the Ca2+-ATPase of the sarcoplasmic reticulum.3 An article in this issue of Circulation by Margossian et a14 offers another lead concerning why hearts fail: this time at the posttranslational level of regulation. Their See p 1720 investigation provides evidence that proteolytic breakdown of a myosin light chain (LC2) may be an important mechanism that contributes to the contractile failure in IDC. The study by Margossian et al raises some important questions: How would activity and regulation of myofilaments be expected to change with the loss of LC2? Does this explain altered myofilament activity and regulation seen in IDC? What else might happen to the myofilaments that alters their function in IDC and other types of heart failure?
What Does Myosin Light Chain 2 Do? LC2 modifies the actin-myosin reaction and its regulation by troponin-tropomyosin. This appears to occur by its interaction with myosin heavy chain and by its position on the thick filament, both of which may be altered by divalent metal binding or phosphorylation.
The opinions expressed in this editorial comment are not necessarily those of the editors or of the American Heart Association. LC2 is noncovalently attached to the myosin heavy chain in 1:1 stoichiometry at a strategically important domain where the head and neck of myosin meet at the S1-S2 junction.5 LC2 binds Ca2+ ions, but the binding is too slow and of too low an affinity to trigger activation of the myofilaments.6 However, long-term changes in LC2 Ca2' and Mg2`binding might modulate the actin-myosin reaction. LC2 is also a substrate for a Ca2+-calmodulindependent protein kinase (MLCK).6,7 Unlike the case in smooth muscle, phosphorylation of LC2 by MLCK does not turn on striated myofilament contraction. It is apparent, however, that LC2 phosphorylation in heart muscle could move myosin heads away from the thick filament and therefore increase the affinity of myosin for actin.7 Although it is not entirely clear to what extent metal binding and LC2 phosphorylation determine the contractility of heart cells, it seems probable that if LC2 is missing, the range of control of the actin-myosin reaction would be compromised.
Important ideas about the function of LC2 in myosin activity have come from experiments in which LC2 is reversibly dissociated from myosin preparations or skinned fibers by the use of metal chelators or proteases. Studies with skinned fibers are particularly powerful because it is possible to make a measurement on a fiber segment and then repeat the measurement after partial extraction and restoration of the LC2. When Hofmann et a18 performed these experiments using skinned skeletal muscle fibers, they showed that LC2 removal decreased a high-velocity phase of unloaded shortening. They concluded that the dissociation of the myosin crossbridge from actin is slowed down when LC2 is partially removed, an interpretation that agrees with the in vitro experiments reported by Margossian et al. Hofmann et al showed also that the removal of LC2 has no effect on maximum tension. However, at submaximally activating levels of free Ca2' there was an increase in tension. The effect of LC2 removal therefore caused a leftward shift of the force-pCa relation. This result indicated that, compared with native myosin, LC2deficient myosin has relatively high affinity for actin. This is predicted from the experiments of Wagner and Stone,9 whose preparations of myosin heads lacking LC2 could bind more easily to reconstituted thin filaments than native heads. Importantly, Hofmann et al showed that stiffness changed in proportion to the tension. Therefore, the effect of LC2 removal on submaximal force is because of an increase in the number of force-generating (strong) crossbridges instead of on the ability of an individual crossbridge to generate force. The increase in force-generating crossbridges helps explain the leftward shift in the force-pCa rela-Circulation Vol 85, No 5 May 1992 tion because thin-filament activation is controlled by the number of strong crossbridges. 10 Based on these findings, it is hypothesized that myofilaments that have lost LC2 should be more sensitive to Ca2+, produce the same maximum force, but have elevated submaximal force. They should have reduced actomyosin ATPase rate and a reduced maximum unloaded shortening velocity. Some but not all of the changes in myofilament activity and regulation predicted from these studies have been seen in myofilament preparations from human cardiomyopathy.11-13 The pCa50 (-log of half-maximally activating free Ca21) for activation of normalized force and ATPase activity has been reported to be the same in preparations from controls and myopathic hearts. In one study,14 however, it was apparent that force developed by skinned fibers from ventricles of patients with IDC showed an increased sensitivity to Ca 2 compared with a nondiseased control preparation. In experiments reported by Hajjar et al,'2 differences in pCa-force relations between skinned fibers from controls and IDC hearts were evident only after treatment with the Ca21 sensitizer, DPI 201-106. As predicted, myofibrillar actomyosin ATPase rate was shown to be reduced in myopathic preparations compared with controls.1"'3 This agrees with the prediction from the study of Margossian et al. However, compared with control hearts, the reduction in maximum myofibrillar ATPase activity was evident in preparations from a variety of cardiac diseases, including IDC.11""3 It is important to realize that the "controls" in the study by Margossian et al were not from disease-free humans but were from patients with other forms of heart failure. This kind of comparison has not been done in the measurements of myofibrillar ATPase.
What Else Might Happen to Myofilaments in
Idiopathic Dilated Cardiomyopathy? In addition to the changes in the heavy and light chains of myosin, there may also be changes in the regulation and structure of thin-filament proteins in human heart failure. Maximum myofibrillar ATPase rate is decreased by the phosphorylation of protein kinase C sites in TnT and TnI with no change in the pCa50 for activation.'5 Whether these sites are phosphorylated to different extents in control and cardiomyopathic preparations is unknown. The isoform population of thin-filament proteins may also change in heart failure. Anderson et al'6 reported that unlike the controls, left ventricular preparations from human failing hearts showed evidence for expression of TnT2, a fetal isoform of troponin T (TNT), the tropomyosin-binding unit of troponin. Although they showed that the expression of TnT2 correlated with a decrease in maximum myofibrillar ATPase rate, no more than 15-20% of the TnT population was determined to be TnT2 in the failed ventricular myofilaments. From studies of the effect of TnT isoforms on actomyosin ATPase rate, it seems doubtful that this change could account entirely for the decrease in ATPase rate.
Some Future Directions
As with most previous studies on the topic, it is revealed but one step in the cascade of changes that lead to heart failure. Even in the case in which the genetic defect is known, it is not understood how the mutation could lead to all the changes seen in structure and function in heart failure. However, it is important that the study by Margossian et al focuses attention on the possibility that posttranslational disturbances could be part of a causal chain of events. What leads to a high activity of the protease that breaks down LC2 will be of great interest to understand. Exactly how the removal of LC2 alters myofilament function and assembly in human hearts will also be of interest. There is clearly a need to investigate how the loss of LC2 affects cardiac myofilaments operating in the steady and presteady state and in which ATPase rate and force are measured simultaneously with precision and fidelity under known levels of protein phosphorylation. The next challenge will be to understand this information in the context of cardiac dynamics and other changes of IDC hearts, especially possible alterations in Ca2+ movements out of and into stores and to and from binding sites.
